• Artrya signs five-year commercial agreement with Cone Health, its third U.S. foundation partner
• Salix® Coronary Anatomy platform to be licensed as a SaaS platform with a fixed monthly subscription fee
• Salix® Coronary Plaque module to generate fee-per-scan revenue

Artrya Limited (ASX: AYA), a medical technology company commercialising its Salix® AI-powered cloud platform, has signed a five-year commercial agreement with Cone Health, its third U.S. foundation partner. Under the contract, Salix® Coronary Anatomy will be licensed as a SaaS platform with a fixed monthly subscription fee, while assessments performed using the Salix® Coronary Plaque module will generate fee-per-scan revenue. Cone Health, a leading not-for-profit health system in North Carolina, has worked collaboratively with Artrya to integrate the Salix® platform following the signing of a strategic partnership agreement in June 2024. The onboarding of Cone Health will be managed and supported by Artrya's recently established Customer Success team in Atlanta, Georgia, which is a key strategy to build successful U.S. commercial operations. This agreement marks another step forward in Artrya's accelerating U.S. commercial operations, as the company has now successfully converted all three of its U.S. foundation partners to commercial customers.

The agreement with Cone Health has a minimum value of US$0.45M for the use of the Salix® Coronary Anatomy platform, with additional per-scan revenue from the Salix® Coronary Plaque module over a five-year term.

Artrya will focus on growing the use of the Salix® platform and plaque module throughout its customer base as it moves into 2026.